Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl)indole derivatives: Multi-target compounds with dual antimicrobial and anti-inflammatory activities

doi:10.21203/rs.2.17036/v4

Download PDF

Research article

Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl)indole derivatives: Multi-target compounds with dual antimicrobial and anti-inflammatory activities

https://doi.org/10.21203/rs.2.17036/v4

This work is licensed under a CC BY 4.0 License

Journal Publication

published 30 Mar, 2020

Read the published version in BMC Chemistry →

You are reading this latest preprint version

Three series of 2-(4-methylsulfonylphenyl) indole derivatives have been designed and synthesized. The synthesized compounds were evaluated for their antimicrobial, COX inhibitory and anti-inflammatory activities. Compound 7g was identified to be the most potent antibacterial candidate against strains of MRSA , E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii , respectively with safe therapeutic dose. Compounds 7a-k, 8a-c and 9a-c showed good anti-inflammatory activity with high selectivity toward COX-2 in comparison with reference drugs indomethacin and celecoxib. Compounds 9a-c were found to release moderate amounts of NO to decrease the side effects associated with selective COX-2 inhibitors. A molecular modeling study for compounds 7b, 7h, and 7i into COX-2 active site correlated with results of in vitro COX-2 inhibition assays.

Medicinal Chemistry

antimicrobial

indomethacin analogues

COX-2 inhibitors

nitric oxide

anti-inflammatory

Bacterial resistance reached a dangerous level due to the misuse of antibiotics thus searching for new antimicrobial agents is a significant issue [1]. Furthermore, the administration of multiple drugs to relieve inflammation associated with a bacterial infection may have some secondary health problems and may increase adverse effects [2]. Unfortunately, few drugs possessed these two activities in a single compound. Therefore, there are continuous trails to develop a monotherapy against inflammation due to microbial infection (dual antimicrobial / anti-inflammatory agent) with minimal adverse effects and high safety margin [3].

The nonsteroidal anti-inflammatory drugs (NSAIDs) are used as the primary remedy for pain, fever, and inflammation through inhibition of cyclooxygenase (COX) enzymes [4-6]. Selective COX-2 inhibitor drugs like valdecoxib I, celecoxib II and rofecoxib III relieve inflammation without any gastric side effects [7] (Fig. 1). Despite less gastric irritation of selective COX-2 inhibitors, they showed a few cardiovascular issues consisting of myocardial infarction and high blood pressure [8, 9], leading to the withdrawal of both rofecoxib and valdecoxib from the market [10]. The cause of cardiovascular issues may be due to inhibition of vasodilatory prostacyclin (PGI₂) and an increase in the level of platelet activator thromboxane A₂ (TxA₂) [11]. Nitric oxide (NO) showed vasodilator activity and inhibition of platelet aggregation [12]. Accordingly, attachment of NO donor moiety to selective COX-2 inhibitors may be beneficial to overcome the cardiovascular side effects [13, 14].

A lot of biologically aryl hydrazone derivatives with antimicrobial activity are found in many literatures [15-17] which include nitrofurantoin IV [18, 19]. Additionally, indole-based indomethacin V is a potent NSAID used for the treatment of inflammatory diseases such as rheumatoid arthritis and osteoarthritis [20]. Still, due to its high selectivity for COX-1 inhibition and its acidic nature, it had an apparent ulcerogenic effect [21].

Herein, we aimed to make molecular hybridization of the indole part of indomethacin with p-methylsulfonyl phenyl part of selective COX-2 inhibitors to match the overall structure of coxibs [presence of a diaryl heterocycle bearing one sulfonamide (SO₂NH₂) or methylsulfonyl (SO₂CH₃) group] [22]. Keep in mind the presence of arylhydrazone derivatives at position 3 in indole with the hope to get compounds with dual antimicrobial / anti-inflammatory activity (Fig. 2).

2.1.Chemistry

The compounds were synthesized through a series of reactions illustrated in scheme 1, 2. The reaction of p-methylsulfonyl acetophenone (3) with 4-un/substituted phenylhydrazine HCl under Fischer indole synthesis conditions yielded indole derivatives (5a-c) that are converted to indole-3-carbaldehyde derivatives (6a-c) by Vilsmeir Haack's formylation reaction using POCl₃ and DMF (Scheme 1).

IR spectra for compounds 6a-c showed significant bands at 3205-3320 cm^-1 of indole NH, 1657-1670 cm^-1of C=O and 1150, 1300 cm^-1 of SO₂. ¹H NMR spectra showed a signal at δ 10.00 - 10.04 ppm of an aldehydic proton (H-C=O), 3.17-3.21 ppm of SO₂CH₃ and 12.92-12.62 ppm of indole NH which is D₂O exchangable.

Indole-3-carbaldehyde derivatives (6a-c) were reacted with 4-substituted phenylhydrazine HCl to give hydrazone derivatives (7a-k) in good yield. The structure elucidation of hydrazone derivatives (7a-k) was based on IR, ¹H NMR, and¹³C NMR spectral data. IR spectra showed bands at 1593-1597 cm^-1 for C=N and disappearance of the carbonyl absorption band at 1657-1670 cm^-1which confirm hydrazone formation. ¹H NMR spectra showed a signal at δ 8.24-8.36 ppm of hydrazone proton (H-C=N), 10.03-10.73 ppm of hydrazone NH which is D₂O exchangeable, 12.00 ppm for NH indole which is D₂O exchangeable and disappearance of an aldehydic proton at δ 10.00 – 10.04 ppm which confirm hydrazone formation. ¹³C NMR spectra showed a peak at 143-149 ppm of hydrazone carbon (C=N) which confirm hydrazone formation.

On the other hand, benzimidazole derivatives (8a-c) are synthesized from the reaction of Indole-3-carbaldehyde derivatives (6a-c) with 4-chloro-o-phenylenediamine in the presence of sodium metabisulphite. IR spectra showed bands at 3272-3382 cm^-1 (indole NH, benzimidazole NH) and disappearance of the carbonyl absorption band at 1657-1670 cm^-1. ¹H NMR spectra showed the disappearance of an aldehydic proton at δ 10.00-10.04 ppm and the appearance of a signal at δ (12.37-12.45) ppm of benzimidazole NH (D₂O exchangeable) in addition to a signal at δ 12.04-12.18 ppm of indole NH (D₂O exchangeable).

Oxime derivatives (9a-c) resulted from the reflux of the reaction of Indole-3-carbaldehyde derivatives (6a-c) with hydroxylamine HCl. IR spectra lacked the carbonyl absorption band at 1657-1670 cm^-1and showed absorption bands at 3272-3382 cm^-1 (NH, OH) and 1597 cm^-1 (C=N). ¹H NMR spectra showed a singlet signal at δ 8.32 ppm of azomethine proton H-C=N, 10.89 ppm of OH (D₂O exchangeable) in besides to signal at δ 11.79-12.04 ppm of indole NH (D₂O exchangeable) and disappearance of an aldehydic proton at δ 10.00-10.04 ppm which confirm oxime formation.

2.2.Biological evaluation

2.2.1 Antimicrobial screening

The antimicrobial study was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The University of Queensland (Australia). Evaluation of all synthesized compounds for their antimicrobial activities was done against five pathogenic bacteria, methicillin-resistant Staphylococcus aureus (ATCC 43300) as Gram-positive bacteria, Escherichia coli (ATCC 25922), Klebsiella pneumonia (ATCC 700603), Acinetobacter baumannii (ATCC 19606) and Pseudomonas aeruginosa (ATCC 27853) as Gram-negative bacteria and antifungal activity against two pathogenic fungal strains Candida albicans (ATCC 90028) and Cryptococcus neoformans var. grubii (H99; ATCC 208821) (Table 1).

Results revealed that hydrazone derivatives 7c, 7e, 7f, 7h, and 7j have moderate antibacterial activity against Gram-negative A. baumannii with growth inhibition 43.29, 43.64, 66.69, 51.82 and 46.23 %, respectively. While the hydrazone derivatives 7a, 7g, and 7i have high antibacterial activity against MRSA bacteria and E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii with growth inhibition ranged from 85.76 to 97.76%.

Additionally, the oxime derivatives 9a showed moderate antibacterial activity against Gram-negative A. baumannii with growth inhibition 42.1%, while benzimidazole derivatives (8a-c) showed weak antibacterial activity.

On the other hand, all compounds have weak antifungal activity against C. albicans and C. neoformans var. grubii.

Minimal inhibitory concentrations (MIC µg/mL) measurements were performed for compounds with significant microbial growth inhibition (7a, 7g, and 7i) using ceftriaxone and amphotericin B as a reference drug for antibacterial and antifungal activity, respectively.

As shown in Table 2, compounds 7a,7g and 7i have the best antibacterial activity comparable to that of ceftriaxone against MRSA, E. coli, K. pneumoniae, P. aeruginosa and A. baumannii, respectively.

The safety margin for the active compounds to human cells was determined through cytotoxicity against human embryonic kidney cell line and hemolysis of human red blood cells. The tested compounds 7a, 7g, and 7i were tolerated and non-toxic to human cells as the cytotoxic and hemolytic dose was higher than the therapeutic dose (Table 2).

Compound 7a lacked general nonspecific toxicity, as the largest therapeutic dose (16 µg/ml against A. baumannii) was lower than the cytotoxic and hemolytic concentration (>32, >32 µg/mL respectively). Also, compound 7g showed safe therapeutic concentration against all tested microbes except for A. baumannii (4 µg/mL) which is near to cytotoxic concentration (4.2 µg/mL). Otherwise, the therapeutic concentration of compound 7i against all tested microbes was safe except for A. baumannii (4 µg/mL), which is higher than the cytotoxic concentration (2.987 µg/mL).

2.2.2 In vitro cyclooxygenase (COX) inhibition assay

The in vitro assay evaluated the ability of compounds 7a-k, 8a-c, and 9a-c to inhibit Ovine COX-1 and human recombinant COX-2. All tested compounds have weak COX-1 inhibition activity (IC₅₀ = 9.14 – 13.2 µM) in comparison with indomethacin (IC₅₀ = 0.039 µM). They also exerted potent COX-2 inhibitory activity (IC₅₀ = 0.1 – 0.31 µM) with high COX-2 selectivity (SI = 132 – 31.29) in comparison with reference drugs, indomethacin and celecoxib.

Hydrazone derivatives 7a-k showed potent COX-2 inhibitory activity (IC₅₀ = 0.10 – 0.31 µM) with high selectivity (SI = 132 – 31.29) more than other compounds. Likewise, benzimidazole 8a-c and oxime derivatives 9a-c showed good COX-2 inhibitory activity (IC₅₀ = 0.13 – 0.35 µM) in comparison with reference drugs.

Generally, all tested compounds were more selective toward the COX-2 enzyme (SI = 31.29 - 132) than indomethacin (SI = 0.079) (Table 3) because the size of synthesized compounds was too large to fit into the small COX-1 active site in addition to the presence of diaryl structure bearing SO₂CH₃ or SO₂NH₂ group.

2.2.3 In vivo anti-inflammatory activity

The results listed in (Table 4) showed that compounds 7a-k, 8a-c, and 9a-c offered good anti-inflammatory activity (56.4 – 93.5% reduction of inflammation) after 6 h. in comparison with celecoxib and indomethacin (94.7, 96.6 % reduction of inflammation, respectively) after 6 h.

Hydrazone derivatives (7a-k) showed good anti-inflammatory activity (66.3 – 93.5% reduction of inflammation) after 6 h., Compounds that contained two SO₂CH₃ groups or one SO₂CH₃ and one SO₂NH₂ group (7b, 7c, 7d, 7e, 7h, and 7i) showed a reduction of inflammation by 93.5, 82.5, 78.6, 79.9, 92.7 and 90.1% after 6 h, respectively, more than other derivatives.

Also, benzimidazole and oxime derivatives (8a-c, 9a-c) showed good inhibition of inflammation ranged from 56.4 - 76.2 % % after 6 h.

Compounds 7b, 7c, 7h and 7i that showed the highest COX-2 inhibitory activity (IC₅₀=0.1, 0.11, 0.11 and 0.1 respectively) with high selectivity (S.I. = 124.2, 103.7, 112.7 and 132 respectively) were found to have excellent anti-inflammatory activity (edema inhibition= 93.5, 82.5, 92.7 and 90.1%, respectively) after 6 h.

2.2.4 In vitro nitric oxide release

The NO-releasing properties of compounds 9a-c were assessed in phosphate buffer of pH 7.4 with Griess reagent [23]. As shown in Table 5, compounds 9a-c were found to release moderate amounts of NO compared to the sodium nitrite standard solution, which may explain that the desired action of NO is mediated systemically in the biological system [24]. Therefore, the insertion of nitric oxide releasing group (oxime) can offer a method to decrease the cardiovascular side effects of selective COX-2 inhibitors.

2.2.5 Structure-activity relationship

Presence of arylhydrazone moiety 7a-k at position 3 of indole can possess antimicrobial activity against strains of Gram-positive MRSA bacteria and Gram-negative E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii beside their COX-2 inhibitory activity.

Concerning the anti-inflammatory activity, replacement of methyl group in position 2 in indomethacin by p-methylsulfonyl phenyl moiety increased COX-2 selectivity through increasing the interaction with a hydrophobic residue of COX-2 active site [25]. In addition, the presence of two SO₂CH₃ groups or one SO₂CH₃ and one SO₂NH₂ group (7b, 7c, 7d, 7e, 7h, and 7i) has COX-2 selectivity more than other derivatives.

Replacement of acidic center (CH₂COOH) moiety in position 3 in indomethacin by benzimidazole moiety 8a-c, as a rigid isostere of p-chlorobenzoyl moiety of indomethacin, enhances the anti-inflammatory activity and COX-2 selectivity.

2.3.Molecular modeling

To understand the nature of the interaction of the most active synthesized compounds and COX-2 active site, a molecular docking study was performed using crystal structure data for COX-2 (PDB: ID 3LN1) active site obtained from protein data bank [26]. Molecular modeling of compounds 7h, 7i, 7b, and co-crystallized ligand, celecoxib was performed using MOE 2018.0101 modeling software.

The docking results of compounds 7h, 7i, 7b, and celecoxib were presented in (Table 6). Hydrazone derivatives 7b, 7h, and 7i have been fully fitted within COX-2 active site with high affinity (-17.19, -16.71 and -16.42 Kcal/mol, respectively) in assessment with celecoxib (-14.12 kcal/mol). Compounds 7b, 7h, and 7i contained one SO₂CH₃ and one SO₂NH₂ group or two SO₂CH₃ groups that formed hydrogen bonds with different amino acids (Leu338, Arg499, Ser339, Val335, Arg106, and His75). Besides, the indole ring of compound 7h and 7i offered hydrophobic interaction with Val509 (Fig. 3, 4). Thus, the molecular docking results ensure that compounds 7b, 7h and 7i bind to COX-2 active site with the same manner of celecoxib.

Three series of 2-(4-methylsulfonylphenyl) indole derivatives 7a-k, 8a-c, and 9a-c were evaluated for their antimicrobial and anti-inflammatory activities.

The results showed that arylhydrazone derivatives 7a-k exhibited moderate to good levels of antimicrobial activity. In particular, compounds 7a, 7g, and 7i showed the highest antimicrobial activity against strains of MRSA bacteria and many species of Gram-negative with growth inhibition ranged from 85.76% to 97.76%.

Regarding anti-inflammatory activity, all synthesized compounds 7a-k, 8a-c and 9a-c showed potent anti-inflammatory (56.4 – 93.5% reduction of inflammation after 6 h.) and selective COX-2 inhibitory activity (IC₅₀ = 0.1 – 0.31 µM, SI = 132 – 31.29) more than indomethacin. Besides, oxime derivatives 9a-c showed good selective COX-2 inhibitory activity with moderate in vitro nitric oxide release, which can offer valuable drug design to decrease the cardiovascular problems.

The molecular modeling study ensured in vitro COX-2 inhibition assay results. Compounds 7b, 7h, and 7i fitted to a COX-2 enzyme similar to celecoxib.

These results suggested that the presence of methylsulfonyl moiety in the indole ring offered an increase in COX-2 selectivity more than the reference drug indomethacin. Also, hybridization of methylsulfonyl and arylhydrazone moiety with an indole ring, providing valuable design for the development of compounds with dual antimicrobial/anti-inflammatory activity. Many investigations are currently undergoing to determine the mechanism of action of these compounds.

4.1 Chemistry

A Thomas-Hoover capillary apparatus used to determine melting points. Infrared (IR) spectra were recorded as films on KBr plates using the FT-IR spectrometer.

Thin-layer chromatography (Merck, Darmstadt, Germany) was used for monitoring the reaction mixture, purity, and homogeneity of the synthesized compounds. UV was used as the visualizing agent.

¹H NMR and ¹³C NMR spectra were measured on a Bruker Avance III 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR (Bruker AG, Switzerland) with BBFO Smart Probe and Bruker 400 AEON Nitrogen-Free Magnet, Faculty of Pharmacy, Beni-Suef University, Egypt in DMSO-d₆ with TMS as the internal standard, where J (coupling constant) values are estimated in Hertz (Hz) and chemical shifts were recorded in ppm on δ scale.

Microanalyses for C, H, and N were carried out on Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA) at the Microanalytical unit of Al Azhar University, Egypt and all compounds were within + 0.4% of the theoretical values.

p-Methylthioacetophenone (2) and p-methylsulfonyl acetophenone (3) and 5-Un/substituted-2-(4-(methylsulfonyl) phenyl)-1H-indole (5a-c) were prepared according to a previous procedure [13]. The compounds were confirmed by matching their physical properties with the reported ones.

4.1.1. General procedure for synthesis of 5-substituted-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde 6a-c

A mixture of phosphorous oxychloride POCl₃(1.53 g, 10 mmol) and DMF (0.73 g, 10 mmol) was stirred for 30 minutes at room temperature, the solution of respective indole (1 mmol) in DMF (5 mL) was added slowly to the mixture which allowed to stir overnight. The reaction mixture was poured into ice-cold water and neutralized with 40% NaOH. The separated solid was filtered, dried and recrystallized from ethyl alcohol (yield: 70-80%).

4.1.1.1. 2-(4-(Methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6a)

Yellow solid; Yield 70%; mp 232-235 °C; IR (KBr, cm^-1) 3205 (NH), 3065-3042 (CH aromatic), 2929-2871 (CH aliphatic), 1657 (C=O), 1305, 1150 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.21 (s, 3H, SO₂CH₃), 7.27-7.36 (m, 2H, indole H-5, H-6), 7.57 (d, 1H, J = 8 Hz, indole H-7), 8.08 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.15 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 8.26 (d, 1H, J = 7.6 Hz, indole H-4), 10.04 (s, 1H, aldehydic H), 12.64 (s, 1H, indole NH, D₂O exchangeable). Anal. Calced for C₁₆H₁₃NO₃S: C, 64.20; H, 4.38; N, 4.68. Found: C, 64.48; H, 4.40; N, 4.84.

4.1.1.2. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6b)

Brown solid; Yield 80%; mp 244-246 °C; IR (KBr, cm^-1) 3279 (NH), 3059-3029 (CH aromatic), 2927-2856 (CH aliphatic), 1670 (C=O), 1301, 1148 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.45 (s, 3H, CH₃), 3.17 (s, 3H, SO₂CH₃), 7.17 (d, 1H, J = 8 Hz, indole H-6), 7.46 (d, 1H, J = 8 Hz, indole H-7), 8.06-8.14 (m, 5H, indole H-4, phenyl H-2, H-3, H-5, H-6), 10.00 (s, 1H, aldehydic H), 12.62 (s, 1H, indole NH, D₂O exchangeable). Anal. Calced for C₁₇H₁₅NO₃S: C, 65.16; H, 4.82; N, 4.47. Found: C, 65.27; H, 4.68; N, 4.52.

4.1.1.3. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6c)

Yellow solid; Yield 72%; mp 195-197 °C; IR (KBr, cm^-1) 3320 (NH), 3064-3027 (CH aromatic), 2928-2853 (CH aliphatic), 1661 (C=O), 1302, 1146 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.18 (s, 3H, SO₂CH₃), 7.2 (d, 1H, J = 8Hz, indole H-6), 7.58 (s, 1H, indole H-4), 7.91 (d, 1H, J = 9.6 Hz, indole H-7), 8.09 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.14 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 10.00 (s, 1H, aldehydic H), 12.92 (s, 1H, indole NH, D₂O exchangeable). Anal. Calced for C₁₆H₁₂FNO₃S: C, 60.56; H, 3.81; N, 4.41. Found: C, 60.73; H, 3.72; N, 4.62.

4.1.2. General procedure for synthesis of 5-substituted-3-((2-(4- substituted- phenyl)hydrazono) methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole 7a-k

A mixture of an ethanolic solution of respective indole-3-carbaldehyde derivative (6a-c) (1 mmol) and 4-substituted phenylhydrazine HCl (1 mmol) was heated under reflux for 4-6 hours in the presence of a few drops of glacial acetic acid. After cooling, the reaction mixture was poured into ice-cold water and the separated solid was filtered, dried and recrystallized from methanol (yield: 73-92%).

4.1.2.1. 3-((2-(4-Fluorophenyl)hydrazono)methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole (7a)

Brown solid; Yield 73%; mp 204-206°C; IR (KBr, cm^-1) 3282-3317 (indole NH, hydrazone NH), 3063 (CH aromatic), 2927-2843 (CH aliphatic), 1597 (C=N), 1302, 1148 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.26 (s, 3H, SO₂CH₃), 7.04-7.18 (m, 4H, phenyl hydrazone H-3, H-5, indole H-5, H-6), 7.44 (d, 1H, J = 8 Hz, indole H-4), 7.59 (d, 2H, J = 8.4 Hz, phenyl hydrazone H-2, H-6), 7.99 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.12 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 8.27 (s, 1H, CH), 8.4 (d, 1H, J = 8 Hz, indole H-7), 10.01 (s, 1H, hydrazone NH, D₂O exchangeable), 11.79 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 43.0 (SO₂CH₃), 110.4, 111.9, 112.7, 115.2, 120.3, 125.6, 126.2, 128.0, 129.7, 132.1, 135.7, 136.4, 137.3, 140.2, 143.6 (CH=N), 154.7, 157.1. Anal. Calced for C₂₂H₁₈FN₃O₂S: C, 64.85; H, 4.45; N, 10.31. Found: C, 65.08; H, 4.33; N, 9.95.

4.1.2.2. 2-(4-(Methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl)hydrazono)methyl)-1H-indole (7b)

Yellow solid; Yield 85%; mp 228-230°C; IR (KBr, cm^-1) 3262-3309 (indole NH, hydrazone NH), 3017 (CH aromatic), 2934-2863 (CH aliphatic), 1593 (C=N), 1299, 1150 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.11 (s, 3H, SO₂CH₃), 3.33 (s, 3H, SO₂CH₃), 7.17 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.24-7.33 (m, 2H, indole H-5, H-6), 7.51 (d, 1H, J = 8 Hz, indole H-4), 7.75 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.13 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.3 (s, 1H, CH), 8.4 (d, 1H, J = 8 Hz, indole H-7), 10.72 (s, 1H, hydrazone NH, D₂O exchangeable), 11.98 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 43.9 (SO₂CH₃), 44.8 (SO₂CH₃), 110.5, 111.2, 112.2, 121.5, 122.7, 124.1, 125.7, 127.9, 128.7, 129.5, 130.2, 136.8, 137.3, 137.6, 137.8, 140.6, 149.8 (CH=N). Anal. Calced for C₂₃H₂₁N₃O₄S₂: C, 59.08; H, 4.53; N, 8.99. Found: C, 59.27; H, 4.68; N, 9.12.

4.1.2.3. 4-(2-((2-(4-(Methylsulfonyl)phenyl)-1H-indol-3-yl)methylene)hydrazinyl)benzene sulfonamide (7c)

Yellow solid; Yield 83%; mp 203-204°C; IR (KBr, cm^-1) 3298-3325 (NH₂, indole NH, hydrazone NH), 3014 (CH aromatic), 2924-2853 (CH aliphatic), 1593 (C=N), 1276, 1089 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.11 (s, 3H, SO₂CH₃), 7.17 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.24-7.33 (m, 2H, indole H-5, H-6), 7.5 (d, 1H, J = 8 Hz, indole H-4), 7.75 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.13 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.36 (s, 1H, CH), 8.39 (d, 1H, J = 8 Hz, indole H-7), 10.71 (s, 1H, hydrazone NH, D₂O exchangeable), 11.97 (s, 1H, indole NH, D₂O exchangeable), NH₂ not distinguished; ¹³C NMR (DMSO-d₆) δ (ppm): 43.9 (SO₂CH₃), 110.5, 111.2, 112.2, 121.5, 122.7, 124.1, 125.7, 127.9, 128.7, 129.5, 130.2, 136.8, 137.3, 137.6, 137.8, 140.6, 149.8 (CH=N). Anal. Calced for C₂₂H₂₀N₄O₄S₂: C, 56.39; H, 4.30; N, 11.96. Found: C, 56.45; H, 4.17; N, 12.28.

4.1.2.4. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl) hydraz- ono) methyl )-1H-indole (7d)

Brown solid; Yield 85%; mp 262-264°C; IR (KBr, cm^-1) 3319-3340 (indole NH, hydrazone NH), 3023 (CH aromatic), 2932-2856 (CH aliphatic), 1595 (C=N), 1300, 1140 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.55 (s, 3H, CH₃), 3.11 (s, 3H, SO₂CH₃), 3.31 (s, 3H, SO₂CH₃), 7.12-7.18 (m, 3H, indole H-6, phenyl hydrazone H-3, H-5), 7.4 (d, 1H, J = 8.4 Hz, indole H-7), 7.76 (d, 2H, J = 8.4 Hz, phenyl hydrazone H-2, H-6), 7.92 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.11 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.35 (s, 1H, CH), 8.18 (s, 1H, indole H-4), 10.71 (s, 1H, hydrazone NH, D₂O exchangeable), 11.88 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 22.0 (CH₃), 44.0 (SO₂CH₃), 44.8 (SO₂CH₃), 110.1, 111.2, 111.9, 122.2, 125.6, 126.0, 126.8, 127.8, 128.7, 129.5, 129.8, 130.1, 135.7, 136.9, 137.8, 140.6, 149.8 (CH=N). Anal. Calced for C₂₄H₂₃N₃O₄S₂: C, 59.86; H, 4.81; N, 8.73. Found: C, 59.67; H, 4.82; N, 8.97.

4.1.2.5. 4-(2-((5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)methylene) hydrazine -yl) benzenesulfonamide (7e)

Yellow solid; Yield 87%; mp 186-188°C; IR (KBr, cm^-1) 3300-3341 (NH₂, indole NH, hydrazone NH), 3023 (CH aromatic), 2927-2854 (CH aliphatic), 1595 (C=N), 1300, 1130 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.1 (s, 3H, CH₃), 3.33 (s, 3H, SO₂CH₃), 7.12-7.18 (m, 4H, phenyl hydrazone H-3, H-5, indole H-4, H-6), 7.39 (d, 1H, J = 8 Hz, indole H-7), 7.76 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.93 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.12 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.18 (s, 2H, NH₂, D₂O exchangeable), 8.35 (s, 1H, CH), 10.7 (s, 1H, hydrazone NH, D₂O exchangeable), 11.88 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 22.0 (CH₃), 43.9 (SO₂CH₃), 110.1, 111.2, 111.9, 122.3, 125.6, 125.9, 127.9, 128.6, 129.5, 129.8, 130.1, 135.7, 136.9, 137.8, 137.8, 140.5, 149.8 (CH=N). Anal. Calced for C₂₃H₂₂N₄O₄S₂: C, 57.24; H, 4.60; N, 11.61. Found: C, 57.56; H, 4.53; N, 11.89.

4.1.2.6. 3-((2-(4-Fluorophenyl)hydrazono)methyl)-5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole (7f)

Yellow solid; Yield 80%; mp 159-161°C; IR (KBr, cm^-1) 3250-3307 (indole NH, hydrazone NH), 3065 (CH aromatic), 2928-2859 (CH aliphatic), 1597 (C=N), 1300, 1146 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.49 (s, 3H, CH₃), 3.4 (s, 3H, SO₂CH₃), 7.02 (d, 2H, J = 8.4 Hz, phenyl hydrazone H-3, H-5), 7.04-7.1 (m, 3H, phenyl hydrazone H-2, H-6, indole H-7), 7.37 (d, 1H, J = 8 Hz, indole H-6), 7.92 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.1 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.18 (s, 1H, indole H-4),8.25 (s, 1H, CH), 10.03 (s, 1H, hydrazone NH, D₂O exchangeable), 11.75 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 22.6 (CH₃), 43.6 (SO₂CH₃), 110.4, 111.5, 112.1, 116.2, 122.3, 125.4, 126.1, 127.8, 129.8, 134.6, 135.7, 136.4, 137.2, 140.2, 143.1 (CH=N), 154.7, 157.0. Anal. Calced for C₂₃H₂₀FN₃O₂S: C, 65.54; H, 4.78; N, 9.97. Found: C, 65.6; H, 4.6; N, 9.94.

4.1.2.7. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-3-((2-(p-tolyl)hydrazono)methyl)-1H-indole (7g)

Brown solid; Yield 84%; mp 166-168°C; IR (KBr, cm^-1) 3214-3306 (indole NH, hydrazone NH), 3023 (CH aromatic), 2926-28658 (CH aliphatic), 1598 (C=N), 1302, 1149 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.32 (s, 3H, CH₃), 2.48 (s, 3H, CH₃), 3.25 (s, 3H, SO₂CH₃), 6.95-7.07 (m, 3H, indole H-6, phenyl hydrazone H-3, H-5), 7.39 (d, 1H, J = 8.4 Hz, indole H-7), 7.62 (s, 2H, NH₂, D₂O exchangeable), 7.80 (d, 2H, J = 8.4 Hz, phenyl hydrazone H-2, H-6), 7.92 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.10 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 8.2 (s, 1H, CH), 8.25 (s, 1H, indole H-4), 9.91 (s, 1H, hydrazone NH, D₂O exchangeable), 11.71 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 20.5 (CH₃), 22.1 (CH₃), 44.0 (SO₂CH₃), 111.0, 111.9, 120.5, 122.5, 125.6, 126.1, 126.8, 127.2, 127.8, 128.1, 129.6, 130.0, 135.2, 136.1, 137.7, 140.7, 144.1 (CH=N). Anal. Calced for C₂₄H₂₃N₃O₂S: C, 69.04; H, 5.55; N, 10.06. Found: C, 68.82; H, 5.68; N, 10.32.

4.1.2.8. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl) hydraz -ono)methyl)-1H-indole (7h)

Bale yellow solid; Yield 92%; mp 187-188°C; IR (KBr, cm^-1) 3265-3337 (indole NH, hydrazone NH),3025 (CH aromatic), 2925-2854 (CH aliphatic), 1593 (C=N), 1321, 1140 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.12 (s, 3H, SO₂CH₃), 3.34 (s, 3H, SO₂CH₃), 7.15-7.20 (m, 3H, phenyl hydrazone H-3, H-5, indole H-6), 7.51 (s, 1H, indole H-4), 7.77 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.04 (d, 1H, J = 8 Hz, indole H-7), 8.14 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.34 (s, 1H, CH), 10.73 (s, 1H, hydrazone NH, D₂O exchangeable), 12.11 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 44.0 (SO₂CH₃), 44.8 (SO₂CH₃), 107.0, 111.3, 112.1, 113.4, 125.9, 127.9, 129.0, 129.5, 130.2, 134.0, 136.5, 137.4, 139.4, 140.9, 149.7 (CH=N), 157.2, 159.5. Anal. Calced for C₂₃H₂₀FN₃O₄S₂: C, 56.89; H, 4.15; N, 8.65. Found: C, 57.17; H, 4.23; N, 8.58.

4.1.2.9. 4-(2-((5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indol-3yl)methylene)hydrazinyl) benzene sulfonamide (7i)

Yellow solid; Yield 82%; mp 212-214°C; IR (KBr, cm^-1) 3260-3315 (NH₂, indole NH, hydrazone NH), 3026 (CH aromatic), 2927 (CH aliphatic), 1594 (C=N), 1295, 1140 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.24 (s, 3H, SO₂CH₃), 7.14 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.51 (s, 1H, indole H-4), 7.67 (d, 1H, J = 8 Hz, indole H-6), 7.76 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.91 (s, 2H, NH₂, D₂O exchangeable), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.03 (d, 1H, J = 8 Hz, indole H-7), 8.13 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.34 (s, 1H, CH), 10.62 (s, 1H, hydrazone NH, D₂O exchangeable), 11.99 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 44.0 (SO₂CH₃), 107.0, 110.6, 112.4, 113.5, 125.9, 127.5, 129.0, 129.2, 130.2, 134.0, 135.5, 136.4, 139.4, 140.8, 141.0, 149.7 (CH=N), 157.2. Anal. Calced for C₂₂H₁₉FN₄O₄S₂: C, 54.31; H, 3.94; N, 11.52. Found: C, 54.67; H, 3.82; N, 11.73.

4.1.2.10. 5-Fluoro-3-((2-(4-fluorophenyl)hydrazono)methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole (7j)

Yellow solid; Yield 82%; mp 200-202°C; IR (KBr, cm^-1) 3217-3250 (indole NH, hydrazone NH), 3065 (CH aromatic), 2928-2863 (CH aliphatic), 1597 (C=N), 1302, 1145 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.33 (s, 3H, SO₂CH₃), 7.01 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.09-7.17 (m, 3H, phenylhydrazone H-2, H-6, indole H-6), 7.5 (s, 1H, indole H-4), 7.94 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.03 (d, 1H, J = 8 Hz, indole H-7), 8.12 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.25 (s, 1H, CH), 10.09 (s, 1H, hydrazone NH, D₂O exchangeable), 11.99 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 44.0 (SO₂CH₃), 107.3, 111.1, 112.0, 112.7, 113.0, 116.3, 125.9, 127.9, 130.1, 134.0, 136.7, 137.9, 140.6, 142.9 (CH=N), 154.7, 157.0, 159.3. Anal. Calced for C₂₂H₁₇F₂N₃O₂S: C, 62.11; H, 4.03; N, 9.88. Found: C, 62.32; H, 4.11; N, 10.16.

4.1.2.11. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-3-((2-(p-tolyl)hydrazono)methyl)-1H-indole (7k)

Brown solid; Yield 75%; mp 151-153°C; IR (KBr, cm^-1) 3220-3270 (indole NH, hydrazone NH),3034 (CH aromatic), 2927, 2860 (CH aliphatic), 1597 (C=N), 1303, 1146 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.23 (s, 3H, CH₃), 3.33 (s, 3H, SO₂CH₃), 6.94 (d, 2H, J = 12 Hz, phenyl hydrazone H-3, H-5), 7.07 (d, 2H, J = 12 Hz, phenyl hydrazone H-2, H-6),7.15 (d,1H, J = 8 Hz, indole H-6), 7.48 (s, 1H, indole H-4), 7.94 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.05 (d, 1H, J = 12 Hz, indole H-7), 8.12 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.24 (s, 1H, CH), 10.01 (s, 1H, hydrazone NH, D₂O exchangable), 11.96 (s, 1H, indole NH, D₂O exchangable; ¹³C NMR (DMSO-d₆) δ (ppm): 20.7 (CH₃), 43.9 (SO₂CH₃), 105.3, 111.4, 112.2, 113.3, 125.9, 126.9, 127.3, 128.2, 129.9, 134.0, 134.8, 137.7, 137.9, 140.5, 144.0 (CH=N), 157.0, 159.3. Anal. Calced for C₂₃H₂₀FN₃O₂S: C, 65.54; H, 4.78; N, 9.97 Found: C, 65.70; H, 5.03; N, 10.14.

4.1.3. General procedure for synthesis of 2-(5-substituted-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-6-chloro-1H-benzo[d]imidazole 8a-c

A mixture of 4-chloro phenylene diamine (0.142 g, 1 mmol), sodium metabisulfite (0.19 g, 1 mmol) and respective indole-3-carbaldehyde derivative (6a-c) (1 mmol) in DMF was heated under reflux for 6 hours. After cooling, the reaction mixture was poured into ice cold water and the separated solid was filtered, dried and recrystallized from ethanol (yield: 60-70%).

4.1.3.1. 5-Chloro-2-(2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzo[d]imidazole (8a)

Yellow solid; Yield 60%; mp 210-212 °C; IR (KBr, cm^-1) 3285-3382 (indole NH, benzimidazole NH), 3065-3021 (CH aromatic), 2926-2853 (CH aliphatic), 1660 (benzimidazole C=N), 1301, 1149 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 3.27 (s, 3H, SO₂CH₃), 7.19-7.22 (m, 2H, indole H-5, benzimidazole H-6), 7.3 (t, 1H, J = 7.4 Hz, indole H-6), 7.47 (s, 1H, benzimidazole H-4), 7.55 (d, 1H, J = 8 Hz, benzimidazole H-7), 7.69 (s, 1H, indole H-7), 7.89-7.92 (m, 3H, phenyl H-2, H-6, indole H-4), 7.99 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 12.18 (s, 1H, indole NH, D₂O exchangeable), 12.45 (s, 1H, benzimidazole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 43.8 (SO₂CH₃), 105.1, 112.4, 116.4, 116.8, 117.5, 120.7, 121.2, 122.5, 123.8, 127.7, 128.0, 129.5, 131.5, 135.3, 136.2, 136.8, 136.9, 140.5, 145.8. Anal. Calced for C₂₂H₁₆ClN₃O₂S: C, 62.63; H, 3.82; N, 9.96. Found: C, 62.89; H, 3.68; N, 10.24.

4.1.3.2. 5-Chloro-2-(5-fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzo[d] imidazole (8b)

Pale yellow; Yield 67%; mp 202-204°C; IR (KBr, cm^-1) 3348-3360 (indole NH, benzimidazole NH), 3008-3063 (CH aromatic), 2854-2928 (CH aliphatic), 1659 (benzimidazole C=N), 1300, 1148 (SO₂);¹H NMR (DMSO-d₆) δ (ppm): 3.29 (s, 3H, SO₂CH₃), 7.13-7.22 (m, 2H, indole H-6, benzimidazole H-6), 7.46 (d, 1H, J = 8 Hz, benzimidazole H-7), 7.55 (s, 1H, indole H-4), 7.66-7.72 (m, 2H, benzimidazole H-4, indole H-7), 7.91 (d, 2H, , J = 8 Hz, phenyl H-2, H-6), 8.02 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 12.25 (s, 1H, indole NH, D₂O exchangeable ), 12.37 (s, 1H, benzimidazole NH, D₂O exchangeable);¹³C NMR (DMSO-d₆) δ (ppm): 43.9 (SO₂CH₃), 105.4, 106.3, 112.1, 113.6, 117.3, 118.3, 122.0, 123.8, 125.2, 127.7, 129.7, 133.5, 136.6, 138.1, 140.4, 140.9, 141.9, 146.3, 149.0. Anal. Calced for C₂₂H₁₅ClFN₃O₂S: C, 60.07; H, 3.44; N, 9.55. Found: C, 60.31; H, 3.20; N, 9.79.

4.1.3.3. 5-Chloro-2-(5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzo[d ]imidazole (8c)

Yellow solid; Yield 70%; mp 217-219 °C; IR (KBr, cm^-1) 3272-3322 (indole NH, benzimidazole NH), 3192, 3072 (CH aromatic), 2927, 2857 (CH aliphatic), 1620 (benzimidazole C=N), 1301, 1149 (SO₂); ¹H NMR (DMSO-d₆) δ (ppm): 2.43 (s, 3H, CH₃),3.27 (s, 3H, SO₂CH₃), 7.12 (d, 1H, J = 8.4 Hz, indole H-6), 7.2 (d, 1H, J = 8.4 Hz, benzimidazole H-6), 7.43-7.47 (m, 2H, indole H-7, benzimidazole H-7), 7.68-7.71 (m, 2H, indole H-4, benzimidazole H-4), 7.88 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 7.98 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 12.04 (s, 1H, indole NH, D₂O exchangeable ), 12.45 (s, 1H, benzimidazole NH, D₂O exchangeable); ¹³C NMR (DMSO-d₆) δ (ppm): 21.7 (CH₃), 43.8 (SO₂CH₃), 104.7, 112.1, 113.2, 118.4, 118.6, 120.1, 122.7, 125.5, 126.2, 127.6, 128.3, 129.4, 130.0, 134.3, 135.2, 136.1, 137.0, 140.4, 145.7. Anal. Calced for C₂₃H₁₈ClN₃O₂S: C, 63.37; H, 4.16; N, 9.64. Found: C, 63.24; H, 4.25; N, 9.88.

4.1.4. General procedure for synthesis of 5-un/substituted-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime 9a-c

A mixture of an ethanolic solution of respective indole-3-carbaldehyde derivative (6a-c) (1 mmol) and hydroxylamine HCl (0.08 g, 1 mmol) was heated under reflux for 4-6 hours in the presence of a few drops of pyridine. After cooling, the reaction mixture was poured into ice-cold water and the separated solid was filtered, dried and recrystallized from ethanol (yield: 55-70%).

4.1.4.1. 2-(4-(Methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9a)

Yellow solid; Yield 62%; mp 199-201°C; IR (KBr, cm^-1) 3282-3385 (indole NH, OH), 3010-3028 (CH aromatic), 2928-2951 (CH aliphatic), 1596 (C=N), 1302, 1146 (SO₂);¹H NMR (DMSO-d₆) δ (ppm): 3.31 (s, 3H, SO₂CH₃), 7.16 - 7.26 (m, 2H, indole H-5, H-6), 7.48 (d, 1H, J = 8 Hz, indole H-7), 7.89 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.10-8.12 (m, 3H, phenyl H-3, H-5, indole H-4), 8.32 (s, 1H, CH), 10.89 (s, 1H, OH, D₂O exchangeable), 11.96 (s, 1H, indole NH, D₂O exchangeable);¹³C NMR (DMSO-d₆) δ (ppm): 44.2 (SO₂CH₃), 106.4, 112.7, 122.4, 125.7, 126.2, 127.9, 129.0, 129.9, 135.6, 136.7, 137.7, 140.7, 143.3 (CH=N). Anal. Calced for C₁₆H₁₄N₂O₃S: C, 61.13; H, 4.49; N, 8.91. Found: C, 61.48; H, 4.61; N, 8.62.

4.1.4.2. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9b)

Yellow solid; Yield 55%; mp 226-228°C; IR (KBr, cm^-1) 3366-3463 (indole NH, OH), 3013-3029 (CH aromatic), 2918-2997 (CH aliphatic), 1598 (C=N), 1298, 1143 (SO₂);¹H NMR (DMSO-d₆) δ (ppm): 3.3 (s, 3H, SO₂CH₃), 7.12 (d, 1H, J = 8 Hz, indole H-6), 7.48 (s, 1H, indole H-4), 7.8 (d, 1H, J = 8Hz, indole H-7), 7.89 (d, 2H, J = 8Hz, phenyl H-2, H-6), 8.11 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.31 (s, 1H, CH), 10.89 (s, 1H, OH, D₂O exchangeable), 12.04 (s, 1H, indole NH, D₂O exchangeable);¹³C NMR (DMSO-d₆) δ (ppm): 43.9 (SO₂CH₃), 107.2, 112.2, 113.3, 126.2, 128.0, 129.5, 133.8, 136.3, 139.3, 140.5, 144.0 (CH=N), 157.1, 159.4. Anal. Calced for C₁₆H₁₃FN₂O₃S: C, 57.82; H, 3.94; N, 8.43. Found: C, 57.58; H, 4.06; N, 8.75.

4.1.4.3. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9c)

Yellow solid; Yield 70%; mp 212-214°C °C; IR (KBr, cm^-1) 3362 (indole NH, OH), 3025-3060 (CH aromatic), 2857-2928 (CH aliphatic), 1597 (C=N), 1300, 1145 (SO₂);¹H NMR (DMSO-d₆) δ (ppm): 2.42 (s, 3H, CH₃), 3.29 (s, 3H, SO₂CH₃), 7.09 (d, 1H, J = 8 Hz, indole H-7), 7.36 (d, 1H, J = 8 Hz, indole H-6), 7.86 (d, 2H, J = 8 Hz, phenyl H-2, H-6),7.94 (s, 1H, indole H-4), 8.09 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.31 (s, 1H, CH), 10.8 (s, 1H, OH, D₂O exchangeable ), 11.79 (s, 1H, indole NH, D₂O exchangeable);¹³C NMR (DMSO-d₆) δ (ppm): 21.7 (CH₃), 44.0 (SO₂CH₃), 107.4, 111.8, 122.2, 125.4, 126.2, 127.7, 129.0, 129.9, 135.5, 136.7, 137.7, 140.5, 144.3 (CH=N). Anal. Calced for C₁₇H₁₆N₂O₃S: C, 62.18; H, 4.91; N, 8.53. Found: C, 62.42; H, 4.83; N, 8.79.

4.2 Biological evaluation

4.2.1 Antimicrobial and antifungal activities

The antimicrobial and antifungal screening was performed according to CO-ADD (The Community for Antimicrobial Drug Discovery) procedures [27].

4.2.2 COX-1/COX-2 inhibition colorimetric assay

Measurement of the ability of the synthesized compounds to inhibit COX isozymes by using colorimetric COX (ovine) inhibitor screening assay kit (Kit catalog number 760111, Cayman Chemical, Ann Arbor, MI, USA) following the manufacturer’s instructions and as mentioned before [28].

4.2.3 Carrageenan-induced rat edema assay

Pretreatment of rats with compounds 7a-k, 8a-c, and 9a-c before injection with carrageenan in rat paw which induces inflammation and then the percentage of paw edema reduction was measured after certain hours according to previously reported procedures [29].

4.2.4 In vitro nitric oxide release assay

Different solutions of the tested compounds 9a-c in DMF were diluted using phosphate buffer (pH 7.4) till a final concentration of 100 µM (test solutions). To 100 µl of different test solutions, 100 µl of N-acetyl cysteine solution was added and the obtained solution was kept in an incubator at 37 °C (treated solutions). The solutions were treated similarly as for a nitrite standard solution with Griess reagent components, 100 µl of sulphanilamide solution was added to each tube of the treated solution, the mixture was left at 25 °C for 5-10 minutes, protected from light. To this mixture 100 µl of the NED solution was added, the mixture was again left for 5-10 minutes at 25 °C, protected from light.

The absorbance of the formed purple color, if any, was measured within 30 minutes at λ 546 nm, a blank experiment was performed under the same conditions, the procedure was repeated three times for each tested compound and the average absorbance values were calculated. The corresponding concentration of nitrite was determined by comparison to the nitrite standard calibration curve and the amount of NO released (revealed by the corresponding nitrite concentration) was calculated as a percentage of moles of NO released from 1 mole of the tested compounds.

4.3Molecular modeling and docking

Molecular modeling studies were performed by using Molecular Operating Environment MOE version 2018.0101. Structures of 7b, 7h, and 7i were built in MOE. The X-ray crystal structure of celecoxib bound to the COX-2 (PDB: ID 3LN1) active site was obtained from the protein data bank at research collaboration for Structural Bioinformatics (RSCB) protein database [PDB].

Preparation of the enzyme for docking by removing the Co-crystallized ligand and water molecules then the enzyme was 3D protonated, in which hydrogen atoms were added to their standard geometry. The conformers generated were docked into the COX-2 receptor with MOE-dock using the triangle matcher placement method and the GBVI/WSA dG scoring function.

A molecular mechanics force field refinement was carried out on the top 30 poses generated. Celecoxib was redocked into the active site of 3LN1 to validate the docking protocol. Amino acid interactions and the hydrogen bond lengths were summarized in (Table 6).

Acknowledgements

The authors extend their appreciation to the Community for Antimicrobial Drug Discovery (CO-ADD) funded by the Wellcome Trust (UK) and The University of Queensland (Australia) for the antimicrobial screening.

Availability of data and materials

The data sets and samples of the compounds used during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

H.M.A.-R. and K R. A. A designed the idea, and the protocol of the whole study; A.M.M.S synthesized the compounds and wrote the experimental parts. A.M.M.S, H.M.A.-R, E.K.A interpreted the spectral data and modeling study. All the authors revised the whole manuscript and responded to reviewers' comments.

Competing interests

The authors declare no conflict of interest.

Funding

Not applicable. (No specific funding or grant).

A. baumannii: Acinetobacter baumannii

C. albicans: Candida albicans

C. neoformans: Cryptococcus neoformans var. grubii

E. coli: Escherichia Coli

GI₅₀: Growth Inhibition of 50 %

K. pneumonia: Klebsilla pneumonia

MIC: Minimum Inhibitory Concentration

MOE: Molecular Operating Environment software

MRSA: Methicillin-resistant Staphylococcus aureus

P. aeruginosa: Pseudomonas aeruginosa

SI: Selectivity Index

[1] E. Akbas, I. Berber, Antibacterial and antifungal activities of new pyrazolo [3, 4-d] pyridazin derivatives, European Journal of Medicinal Chemistry, 40 (2005) 401-405.

[2] V. Alagarsamy, S. Meena, K. Ramseshu, V. Solomon, K. Thirumurugan, K. Dhanabal, M. Murugan, Synthesis, analgesic, anti-inflammatory, ulcerogenic index and antibacterial activities of novel 2-methylthio-3-substituted-5, 6, 7, 8-tetrahydrobenzo (b) thieno [2, 3-d] pyrimidin-4 (3H)-ones, European Journal of Medicinal Chemistry, 41 (2006) 1293-1300.

[3] A.A. Bekhit, A.M. Farghaly, R.M. Shafik, M.M. Elsemary, A.E.-D.A. Bekhit, A.A. Guemei, M.S. El-Shoukrofy, T.M. Ibrahim, Synthesis, biological evaluation and molecular modeling of novel thienopyrimidinone and triazolothienopyrimidinone derivatives as dual anti-inflammatory antimicrobial agents, Bioorganic Chemistry, (2018) 38-46.

[4] E.K. Abdelall, P.F. Lamie, W.A. Ali, Cyclooxygenase-2 and 15-lipoxygenase inhibition, synthesis, anti-inflammatory activity and ulcer liability of new celecoxib analogues: Determination of region-specific pyrazole ring formation by NOESY, Bioorganic & Medicinal Chemistry Letters, 26 (2016) 2893-2899.

[5] A. Zarghi, L. Najafnia, B. Daraee, O.G. Dadrass, M. Hedayati, Synthesis of 2, 3-diaryl-1, 3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors, Bioorganic & Medicinal Chemistry Letters, 17 (2007) 5634-5637.

[6] T. Zebardast, A. Zarghi, B. Daraie, M. Hedayati, O.G. Dadrass, Design and synthesis of 3-alkyl-2-aryl-1, 3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors, Bioorganic & Medicinal Chemistry Letters, 19 (2009) 3162-3165.

[7] K.R. Abdellatif, E.K. Abdelall, W.A. Fadaly, G.M. Kamel, Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1, 3, 5-triarylpyrazoline and 1, 5-diarylpyrazole derivatives as selective COX-2 inhibitors, Bioorganic & Medicinal Chemistry Letters, 26 (2016) 406-412.

[8] T. Grosser, E. Ricciotti, G.A. FitzGerald, The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs, Trends in Pharmacological Sciences, 38 (2017) 733-748.

[9] H.A. Elshemy, E.K. Abdelall, A.A. Azouz, A. Moawad, W.A. Ali, N.M. Safwat, Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1, 3, 5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC, European Journal of Medicinal Chemistry, 127 (2017) 10-21.

[10] C. Patrono, C. Baigent, Coxibs, traditional NSAIDs, and cardiovascular safety post‐precision: What we thought we knew then and what we think we know now, Clinical Pharmacology & Therapeutics, 102 (2017) 238-245.

[11] E.M. Smyth, Thromboxane and the thromboxane receptor in cardiovascular disease, Clinical Lipidology, 5 (2010) 209-219.

[12] S. Xu, G. Wang, Y. Lin, Y. Zhang, L. Pei, H. Yao, M. Hu, Y. Qiu, Z. Huang, Y. Zhang, Novel anticancer oridonin derivatives possessing a diazen-1-ium-1, 2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies, Bioorganic & Medicinal Chemistry Letters, 26 (2016) 2795-2800.

[13] A.M. Shaker, E.K. Abdelall, K.R. Abdellatif, H.M. Abdel-Rahman, Design, synthesis, and biological evaluation of 2-(4-(methylsulfonyl) phenyl) indole derivatives with promising COX-2 inhibitory activity, Journal of Applied Pharmaceutical Science, 8 (2018) 001-008.

[14] K.R. Abdellatif, E.K. Abdelall, R.B. Bakr, Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents, Current Topics in Medicinal Chemistry, 17 (2017) 941-955.

[15] Ł. Popiołek, Hydrazide–hydrazones as potential antimicrobial agents: overview of the literature since 2010, Medicinal Chemistry Research, 26 (2017) 287-301.

[16] Y. Özkay, Y. Tunalı, H. Karaca, İ. Işıkdağ, Antimicrobial activity of a new series of benzimidazole derivatives, Archives of Pharmacal Research, 34 (2011) 1427-1435.

[17] N. Singh, A. Pandurangan, K. Rana, P. Anand, A. Ahamad, A.K. Tiwari, Benzimidazole: A short review of their antimicrobial activities, International Current Pharmaceutical Journal, 1 (2012) 119-127.

[18] G. Verma, A. Marella, M. Shaquiquzzaman, M. Akhtar, M.R. Ali, M.M. Alam, A review exploring biological activities of hydrazones, Journal Of Pharmacy & Bioallied Sciences, 6 (2014) 69-80.

[19] D. Saini, M. Gupta, Hydrazones as potential anticancer agents: An update, Asian Journal of Pharmacy and Pharmacology, 4 (2018) 116-122.

[20] J. Kaur, A. Bhardwaj, Z. Huang, E.E. Knaus, N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation, Bioorganic & Medicinal Chemistry Letters, 22 (2012) 2154-2159.

[21] B.P. Bandgar, R.J. Sarangdhar, S. Viswakarma, F.A. Ahamed, Synthesis and biological evaluation of orally active prodrugs of indomethacin, Journal of Medicinal Chemistry, 54 (2011) 1191-1201.

[22] O. Unsal-Tan, K. Ozadali, K. Piskin, A. Balkan, Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity, European Journal of Medicinal Chemistry, 57 (2012) 59-64.

[23] H.A. El-Sherief, G.E.-D.A. Abuo-Rahma, M.E. Shoman, E.A. Beshr, R.M. Abdel-baky, Design and synthesis of new coumarin–chalcone/NO hybrids of potential biological activity, Medicinal Chemistry Research, 26 (2017) 3077-3090.

[24] G.E.-D.A. Abuo-Rahma, M. Abdel-Aziz, E.A. Beshr, T.F. Ali, 1, 2, 4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities, European Journal of Medicinal Chemistry, 71 (2014) 185-198.

[25] A.G. Habeeb, P. Praveen Rao, E.E. Knaus, Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere, Journal of Medicinal Chemistry, 44 (2001) 3039-3042.

[26] J.L. Wang, D. Limburg, M.J. Graneto, J. Springer, J.R.B. Hamper, S. Liao, J.L. Pawlitz, R.G. Kurumbail, T. Maziasz, J.J. Talley, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life, Bioorganic & Medicinal Chemistry Letters, 20 (2010) 7159-7163.

[27] M. Berger, A. Roller, N. Maulide, Synthesis and antimicrobial evaluation of novel analogues of dehydroabietic acid prepared by CH-Activation, European journal of medicinal chemistry, 126 (2017) 937-943.

[28] A.H. Abdelazeem, S.A. Abdelatef, M.T. El-Saadi, H.A. Omar, S.I. Khan, C.R. McCurdy, S.M. El-Moghazy, Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents, European Journal of Pharmaceutical Sciences, 62 (2014) 197-211.

[29] A.O. El-Nezhawy, A.R. Biuomy, F.S. Hassan, A.K. Ismaiel, H.A. Omar, Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity, Bioorganic & Medicinal Chemistry, 21 (2013) 1661-1670.

Table 1: The antibacterial and antifungal activities (growth inhibition %) for compounds 7a-k, 8a-c and 9a-c at 32 µg/mL concentration.

Compound No.	Sa^a	Ec^b	Kp^c	Pa^d	Ab^e	Ca^f	Cn^g
7a	95.76	96.48	97.64	97.76	96.66	6.28	-64.35
7b	25.62	-8.09	-5.34	3.8	35.54	9.55	-280.7
7c	21.88	3.17	12.8	11.3	43.29	4.13	-110.9
7d	15.6	-5.77	4.86	-8.11	34.95	2.54	-177.2
7e	7.58	-11.49	-14.6	-22.55	43.64	28.66	-59.93
7f	8.33	-9.43	8.05	-7.9	66.69	3.5	-118.8
7g	96.15	86.42	87.53	94.63	85.76	4.88	-57.42
7h	30.26	-13.86	23.59	7.97	51.82	25.34	-99
7i	95.22	96.45	94.4	96.93	94.34	15.32	-104.5
7j	30.59	-2.24	12.27	-0.85	46.23	1.91	-80.19
7k	28.25	-0.72	8.77	2.23	31.42	1.79	-55.44
8a	13.6	-45.65	-22.34	-28.34	-15.51	7.71	-292.1
8b	11.28	-8.78	6.56	14.46	22.42	13.22	-114.4
8c	4.62	-25.19	-8.38	-10	-13.94	1.65	-288.1
9a	-3.37	-12.05	14.84	2.49	42.1	9.15	-254
9b	10.33	-5.88	9.23	7.9	33.26	2.47	-119.3
9c	-2.72	-15.45	1.19	-0.83	33.66	4.88	-136.1

^a MRSA, ^b E. coli, ^c K. pneumoniae, ^d P. aeruginosa, ^e A. baumannii, ^f C. albicans, ^g C. neoformans var. grubii

Table 2: Minimum inhibitory concentrations (MIC µg/mL) of most active compounds 7a, 7g, 7i and reference drugs, ceftriaxone and amphotericin B.

Compound No.	Sa^a	Ec^b	Kp^c	Pa^d	Ab^e	Ca^f	Cn^g	CC₅₀^h	HC₁₀ⁱ
7a	8	<0.25	8	4	16	>32	>32	>32	>32
7g	1	<0.25	1	1	4	>32	>32	4.2	>32
7i	2	<0.25	2	2	4	>32	>32	2.987	>32
Ceftriaxone	32	0.125	16	32	32	NT^j	NT	NT	NT
Amphotericin B	NT	NT	NT	NT	NT	1.56	1.56	NT	NT

^a MRSA, ^b E. coli, ^c K. pneumoniae, ^d P. aeruginosa, ^e A. baumannii, ^f C. albicans, ^g C. neoformans var. grubii,^h CC₅₀ is the concentration at 50% cytotoxicity, ⁱ HC₁₀ is the concentration at 10% hemolysis, ^j Not Tested.

Table 3: In vitro COX-1 and COX-2 inhibition for compounds 7a-k, 8a-c, 9a-c and reference drugs.

Compounds	COX Inhibition (IC₅₀ µM)		Selectivity index^a (SI)
Compounds	COX-1	COX-2	Selectivity index^a (SI)
Celecoxib	14.80	0.05	296
Indomethacin	0.039	0.49	0.079
7a	10.32	0.11	93.81
7b	12.41	0.10	124.10
7c	11.41	0.11	103.72
7d	10.40	0.15	69.33
7e	9.70	0.31	31.29
7f	9.73	0.17	57.23
7g	7.90	0.20	39.50
7h	12.40	0.11	112.72
7i	13.20	0.10	132
7j	10.80	0.11	98.18
7k	8.24	0.21	39.20
8a	10.64	0.13	81.84
8b	9.41	0.15	62.73
8c	11.23	0.12	93.58
9a	10.64	0.13	81.84
9b	9.42	0.21	44.85
9c	8.24	0.24	34.33

^a Selectivity index (COX-1 IC₅₀/COX-2 IC₅₀)

Table 4: Anti-inflammatory activities for compounds 7a-k, 8a-c, 9a-c and reference drug in carrageen-induced rat paw edema test.

(Edema inhibition %)

Edema thickness (mm) ± SEM^a

Compound

6 hours

3 hours

1 hour

1.875 ±0.181

2.232 ±0.235

2.624 ±0.255

Control

96.6

0.075 ±0.004

0.075 ±0.007

70.7

0.768 ±0.050

Indomethacin

94.7

0.100 ±0.005

95.5

0.100 ±0.009

68.9

0.810 ±0.074

Celecoxib

0.151 ±0.007

88.7

0.250 ±0.021

74.1

0.679 ±0.03

93.5

0.123 ±0.009

91.2

0.196 ±0.017

76.1

0.627 ±0.045

82.5

0.331 ±0.011

81.2

0.419 ±0.028

62.7

0.978 ±0.071

78.6

0.405 ±0.018

77.5

0.502 ±0.044

51.6

1.270 ±0.015

79.9

0.381 ±0.007

71.1

0.645 ±0.01

53.9

1.209 ±0.11

79.2

0.394 ±0.01

72.7

0.609 ±0.03

60.5

1.036 ±0.009

67.4

0.618 ±0.045

72.3

0.618 ±0.010

58.5

1.088 ±0.090

92.7

0.138 ±0.006

89.4

0.236 ±0.008

75.4

0.645 ±0.058

90.1

0.187 ±0.015

94.3

0.127 ±0.009

73.1

0.705 ±0.047

0.549 ±0.013

78.6

0.477 ±0.027

64.3

0.936 ±0.064

66.3

0.638 ±0.051

69.1

0.689 ±0.011

55.7

1.162 ±0.088

56.4

0.826 ±0.078

0.937 ±0.046

52.5

1.246 ±0.076

76.2

0.451 ±0.013

68.1

0.712 ±0.066

52.1

1.256 ±0.074

74.2

0.489 ±0.032

71.9

0.627 ±0.05

67.9

0.842 ±0.062

62.3

0.714 ±0.052

61.8

0.852 ±0.073

77.2

0.598 ±0.050

73.4

0.726 ±0.055

80.5

0.700 ±0.024

66.2

1.175 ±0.057

61.7

0.504 ±0.009

68.6

0.435 ±0.033

55.2

0.886 ±0.077

^aEach value represents mean ± SEM (n = 4).

Table 5: The amount of NO released from tested compounds 9a-c in phosphate buffer pH =7.4 (% mol/mol)

Compound No.	Amount of NO released (% mol/mol)±standardization error (in phosphate buffer PH 7.4)
Compound No.	1 h	2 h	3 h	4 h	5 h
9a	0.027±0.002	0.065±0.002	0.194±0.007	0.165±0.002	0.138±0.004
9b	0.086±0.001	0.147±0.003	0.210±0.002	0.198±0.003	0.218±0.005
9c	0.061±0.001	0.130±0.002	0.187±0.001	0.198±0.003	0.225±0.002

Table 6: Molecular docking data for compounds 7b, 7h, 7i and celecoxib in COX-2 active site (PDB ID: 3LN1).

Compound No.

COX-2

Affinity

(kcal/mol)

Affinity

kcal/mol

Distance (in A^o) from

main residue

Functional

group

Interaction

Celecoxib

-14.12

-2.7

-1.6

-0.8

3.07

2.99

3.54

Leu338

Ser339

Arg499

-NH₂

-SO₂

H-donor

H-acceptor

-17.198

-1.5

-0.7

-2.3

3.18

2.70

2.84

Leu338

Arg499
Arg106

-SO₂CH₃

-SO₂

H-donor

H- acceptor

-16.71

-1.4

-2.7

-0.6

3.23
2.83

4.71

Leu338
Arg499

Val509

-SO₂CH₃

-SO₂

-Ph-ring

H-donor

H-acceptor

H-pi

-16.42

-0.9

-0.6

-4.5

-1.5

-0.9

3.36

3.47

2.86

2.94

3.77

Val335

Ser339

His75

Arg106

Val509

-NH

-SO₂CH₃

-SO₂

-Ph-ring

H-donor

H-acceptor

H-pi

Download PDF

Journal Publication

published 30 Mar, 2020

Read the published version in BMC Chemistry →

Editorial decision: Accept
13 Mar, 2020
Editor assigned by journal
09 Mar, 2020
Submission checks completed at journal
08 Mar, 2020
Editor invited by journal
08 Mar, 2020

You are reading this latest preprint version

Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl)indole derivatives: Multi-target compounds with dual antimicrobial and anti-inflammatory activities

Status:

Journal Publication

Version 4

Abstract

Figures

1. Introduction

2. Results And Discussion

3. Conclusion

4. Experimental

Declarations

Abbreviations

References

Tables

Supplementary Files

Status:

Journal Publication

Version 4